Market Trends of Blood Culture Tests Industry
This section covers the major market trends shaping the Blood Culture Tests Market according to our research experts:
Automated Blood Culture Tests are Expected to Grow at a High Pace
With the need for rapid diagnosis of infections and other diseases, the automated blood culture tests segment is expected to grow at significant rates. In addition, a high adaptation of automated equipment and accuracy in the results eliminate the manual errors in the results of automated blood culture tests gaining traction in the market.
According to the World Health Organization, in 2021, an estimated 12 million people were affected by tuberculosis worldwide. Tuberculosis is one of the leading causes of death around the world. The increasing prevalence of bacterial infections, especially in underdeveloped and developing countries, is expected to boost the growth of the bacterial culture testing segment. The advent of novel diagnostic technologies in culture-based tests, reduction of diagnosis time, and early prevention of disease spreading are expected to boost the growth of the market.
The advantages associated with automated blood culture drive the growth of the market. For instance, as per the National Library article published in September 2021, automated blood culture systems are intended to make the processing of blood cultures more efficient. This is accomplished by eliminating the need for blind or terminal subcultures of bottles, reducing the number of times bottles must be handled during processing, standardizing and speeding detection of microbial growth, and maximizing blood culture sensitivity and specificity. Thus, the abovementioned factors are propelling the growth of the market.
North America is Expected to Hold Significant Share
The North American region is expected to have significant market growth over the forecast period, which is mainly attributed to well-established healthcare infrastructure and better access to diagnostics. Technological advancements, awareness regarding early diagnosis, and the treatment of infectious diseases are expected to boost market growth over the forecast period.
The rising burden of chronic diseases in the United States, such as diabetes, thyroid, and other diseases requiring blood tests, will boost the market studied. For instance, as per the National Diabetes Statistics Report, 2020, approximately 34.2 million people, or 10.5% of the US population, had diabetes. Type 1 diabetes accounted for about 5.2% of all diagnosed cases of diabetes, affecting approximately 1.6 million people in the United States.
Furthermore, the launch of technologically advanced blood tests in the country will also positively contribute to market growth. For instance, in January 2022, Eurofins subsidiary empowered launched PFAS Exposure in the United States, the direct-to-consumer at-home test to determine levels of Per- and Polyfluorinated Alkyl Substances (PFAS) in a person's blood and measure 47 of the PFAS forever chemical compounds. Also, in August 2021, Smart Meter launched the glucose monitor for managing gestational diabetes. It provides an easy and reliable way to test, monitor, and manage blood glucose levels, ensuring that all care providers have immediate access to testing results. Thus, the abovementioned factors are propelling the growth of the market.
